Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis

NCT07530224 is registered in ClinicalTrials.gov with Shixiu Wu as lead sponsor.

NCT NCT07530224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Lead sponsor
Shixiu Wu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 25, 2026
Completion date
December 31, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitor-induced dermatitis